Treatment shows promise as adjunctive calciphylaxis therapy

02/14/2013 | Healio

Thrombolytic tissue plasminogen activator was associated with a 30% increase in the survival rate for patients with calciphylaxis, according to a study in the journal JAMA Dermatology. Complications included major and minor bleeding, and six out of 15 patients had blood transfusions.

View Full Article in:


Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA